Therefore, since previous reports showed that PBMCs from normal donors were useful for screening the immunogenicity of cancer-specific mutations [12], we used PBMCs from normal donors who possessed HLA-A*0201 or HLA-A*2402, which are the most popular types in Japan and Western countries. The gene discussed is HLA-A; the disease is cancer.